Advanced prostate cancer treatment is entering a puzzling phase where oncologists increasingly prescribe the same class of drugs even after they have already failed. This pattern challenges conventional wisdom about drug resistance and suggests either therapeutic desperation or undiscovered mechanisms of renewed sensitivity. Analysis of over 1,000 metastatic castration-resistant prostate cancer patients across seven countries reveals that nearly half receive another androgen receptor pathway inhibitor (ARPI) as their primary treatment, despite having already experienced disease progression on a previous ARPI. The specific compounds abiraterone and enzalutamide dominate these sequential approaches, with abiraterone-to-docetaxel representing the most common transition at 16.1% of cases. Surprisingly, 82.6% of patients had received their initial ARPI in earlier disease stages before metastatic spread, indicating these drugs are moving upstream in treatment timelines. Performance status significantly influenced treatment selection, with healthier patients (ECOG 0-1) receiving taxane chemotherapy 42-46% of the time compared to just 29% among those with declining function. This real-world evidence suggests oncologists may be banking on cross-resistance patterns being incomplete, or that sequential ARPI use buys meaningful time while preserving quality of life. However, the strategy raises questions about optimal drug sequencing and whether patients might benefit more from earlier integration of alternative mechanisms like PARP inhibitors, immunotherapy, or newer targeted agents. The dominance of sequential ARPI therapy, while potentially pragmatic, may reflect limited therapeutic options rather than evidence-based optimization for this challenging patient population.